ERBB2 and Thrombocytopenia: A safety analysis of six studies of T-DM1 in HER2-positive breast cancer23, including 884 patients, found that that the most frequent adverse effect was asthenia, followed by nausea and vomiting, while 32% of patients had thrombocytopenia and 23% had elevated transaminases.